Grants per year
- 1 - 25 out of 115 results
Search results
-
Active
Prot #BH-30643-01: A Phase 1/2 Open-Label, Multicenter, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of BH-30643 in Adult Subjects with Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations
Patel, J. D. (PD/PI)
Pharmaceutical Research Associates, Inc., BlossomHill Therapeutics, Inc.
3/28/25 → 3/28/28
Project: Research project
-
Prot #PRT3789-01: A Phase 1 Open-Label, Multi-Center, Safety and Efficacy Study of PRT3789 as Monotherapy and in Combination with Docetaxel in Participants with Advanced or Metastatic Solid Tumors with a SMARCA4 Mutation
Patel, J. D. (PD/PI)
PPD Investigator Services, LLC, Prelude Therapeutics Inc
1/10/25 → 1/10/28
Project: Research project
-
Prot #DS7300-189: A Phase 1b/2, Multicenter, Open-Label Study of Ifinatamab Deruxtecan (I-DXd), A B7H3 Antibody-Drug Conjugate (ADC), in Combination with Atezolizumab with or without Carboplatin as First-Line Induction or Maintenance, in Subjects with Ext
Patel, J. D. (PD/PI)
Quintiles, Inc., Daiichi Sankyo, Inc.
10/25/24 → 10/25/27
Project: Research project
-
Single-cell tracking of the transformation of lung adenocarcinoma to small cell lung cancer
Abazeed, M. (PD/PI), Abazeed, M. (PD/PI), Gopal, P. (Co-Investigator), Gopal, P. (Co-Investigator), Patel, J. D. (Co-Investigator) & Patel, J. D. (Co-Investigator)
U.S. Army Medical Research and Materiel Command
9/30/24 → 9/29/27
Project: Research project
-
Clinical and Immunological Impact of Interleukin-6 Inhibition on Combination Immunotherapy Efficacy and Toxicity for Patients with Advanced Melanoma
Anouti, B. F. (PD/PI) & Patel, J. D. (PD/PI)
9/1/24 → 8/31/25
Project: Research project
-
Prot #TP-CA-002: TEMPUS GEMINI NSCLC SURVEILLANCE STUDY: A Longitudinal Multi-Omic Biomarker Profiling Study of Patients with Non-Small Cell Lung Cancer (NSCLC)
Patel, J. D. (PD/PI)
7/5/24 → 7/5/27
Project: Research project
-
Prot #ORIC‐114‐01: An Open‐Label, Phase 1/2 Study of ORIC‐114 as a Single Agent or in Combination with Chemotherapy, in Patients with Advanced Solid Tumors Harboring an EGFR or HER2 Alteration
Patel, J. D. (PD/PI)
INC Research, LLC, ORIC Pharmaceuticals, Inc.
5/10/24 → 5/10/27
Project: Research project
-
Prot #TAK-500-1001: An Open-label, Dose Escalation and Expansion, Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of TAK-500, a Novel Stimulator of Interferon Genes Agonist, as a
Patel, J. D. (PD/PI)
PPD Investigator Services, LLC, Takeda Development Center Americas, Inc.
4/2/24 → 4/2/27
Project: Research project
-
Prot #20210004: A Randomized, Open-Label, Phase 3 Study of Tarlatamab Compared With Standard of Care in Subjects With Relapsed Small Cell Lung Cancer After Platinum-Based First-Line Chemotherapy (DeLLphi-304)
Patel, J. D. (PD/PI)
2/29/24 → 2/28/27
Project: Research project
-
Prot #EDGE-Lung: A Phase II, Open-Label, Platform Study, to Evaluate Immunotherapy-Based Combinations in Participants With Advanced Non-Small Cell Lung Cancer
Patel, J. D. (PD/PI)
ICON Clinical Research Limited, Gilead Sciences, Inc
2/14/24 → 2/14/27
Project: Research project
-
Prot #EP0031-101: A Modular, Open-label, Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of EP0031 in Patients with Advanced RET-altered Malignancies
Patel, J. D. (PD/PI)
Theradex, Ellipses Pharma Limited
1/19/24 → 1/19/27
Project: Research project
-
Prot #AL8326‐US‐001: A Phase 2 Evaluation of the Safety and Efficacy of AL8326 in ≥ 2nd Line Small Cell Lung Cancer (SCLC) Treatment
Patel, J. D. (PD/PI)
Advenchen Pharmaceuticals, LLC
9/28/23 → 9/28/26
Project: Research project
-
Prot #BDTX‐1535‐101: A Phase 1 Study to Assess BDTX‐1535, an Oral EGFR Inhibitor, in Patients with Glioblastoma or Non‐Small Cell Lung Cancer
Patel, J. D. (PD/PI)
Novella Clinical, LLC, Black Diamond Therapeutics, Inc.
7/21/23 → 7/21/26
Project: Research project
-
Prot #U31402‐A‐U103: A Phase 1 Open‐Label Study of Patritumab Deruxtecan (U3‐1402) in Combination with Osimertinib in Subjects with Locally Advanced or Metastatic EGFR‐mutated Non‐Small Cell Lung Cancer (NSCLC)
Patel, J. D. (PD/PI)
INC Research, LLC, Daiichi Sankyo, Inc.
6/22/23 → 6/22/26
Project: Research project
-
Prot #NU LCMC4: LCMC LEADER Neoadjuvant Screening Trial: LCMC4 Evaluation of Actionable Drivers in Early Stage Lung Cancers
Patel, J. D. (PD/PI)
Lung Cancer Research Foundation
5/31/23 → 5/31/26
Project: Research project
-
Prot #GS-US-576-6220: An Open-label, Multicenter, Phase 2 Study of Sacituzumab Govitecan Combinations in First-line Treatment of Patients with Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) Without Actionable Genomic Alterations
Patel, J. D. (PD/PI)
ICON Clinical Research Limited, Gilead Sciences, Inc
1/11/23 → 1/11/26
Project: Research project
-
Prot #BLU-451-1101: Phase 1/2 Study of BLU-451 in Advanced Cancers with EGFR EXON20 Insertion Mutations
Patel, J. D. (PD/PI)
Medpace Clinical Research LLC, Blueprint Medicines Corporation
9/20/22 → 9/20/25
Project: Research project
-
Cellular plasticity gives rise to phenotypic equilibrium in small cell lung carcinoma
Abazeed, M. (PD/PI), Abazeed, M. (PD/PI), Gopal, P. (Co-Investigator), Kocherginsky, M. (Co-Investigator), Kocherginsky, M. (Co-Investigator), Kocherginsky, M. (Co-Investigator), Patel, J. D. (Co-Investigator) & Patel, J. D. (Co-Investigator)
9/1/22 → 8/31/27
Project: Research project
-
Prot #20200439: A Phase 1b Study Evaluating the Safety and Efficacy of AMG 757 in Combination with AMG 404 in Subjects with Small Cell Lung Cancer (SCLC)
Patel, J. D. (PD/PI)
3/2/22 → 3/2/26
Project: Research project
-
Prot #AFT-46: CHIO3 Trial: CHemotherapy Combined with Immune Checkpoint Inhibitor for Operable Stage IIIA/B Non-Small Cell Lung Cancer
Patel, J. D. (PD/PI)
Alliance Foundation Trials, LLC, AstraZeneca Pharmaceuticals LP
4/21/21 → 4/21/27
Project: Research project
-
Prot #U31402-A-U201: HERTHENA-Lung01: A Phase 2 Randomized Open-Label Study of Patritumab Deruxtecan (U3-1402) in Subjects with Previously Treated Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer (NSCLC)
Patel, J. D. (PD/PI)
INC Research, LLC, Daiichi Sankyo, Inc.
4/9/21 → 4/9/27
Project: Research project
-
Prot #20190135: A Phase 1b, Master Protocol Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 510 in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation
Patel, J. D. (PD/PI)
2/23/21 → 2/23/27
Project: Research project
-
Prot #HCRN LUN18-335/NU MDA20L01: An Open-Label Randomized Phase II Study of Combining Osimertinib with and without Ramucirumab in TKI-naïve EGFR-mutant Locally Advanced or Metastatic NSCLC
Patel, J. D. (PD/PI)
Hoosier Cancer Research Network, Inc., Lilly USA, LLC
1/14/21 → 1/14/27
Project: Research project
-
Prot #IRB17-0547/NU UC20L05: A Randomized Phase I Trial to Evaluate Concurrent Or Sequential Ipilimumab, Nivolumab, and Stereotactic Body Radiotherapy in Patients with Stage IV Non-Small Cell Lung Cancer (COSINR Study)
Patel, J. D. (PD/PI)
The University of Chicago, Bristol-Myers Squibb Company
1/11/21 → 1/11/26
Project: Research project
-
Prot #TAK-788-3001: A Randomized Phase 3 Multicenter Open-label Study to Compare the Efficacy of TAK-788 as First-line Treatment Versus Platinum-Based Chemotherapy in Patients With Non–Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
Patel, J. D. (PD/PI)
PPD Investigator Services, LLC, Takeda Development Center Americas, Inc.
9/10/20 → 9/10/26
Project: Research project